February 10, 2025Open Access

Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

In summary, we identify synergistic molecular cross-talk between the GLP-1R and steroid hormone receptor pathways, with the potential to enhance the anticancer activity of levonorgestrel when combined with semaglutide.

Bookmark

View Full Paper

Cite This Study

Hagemann et al. (Mon,) studied this question.

synapsesocial.com/papers/69db06de00ab073a27839659 https://doi.org/https://doi.org/10.3390/cancers17040598

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Non-genomic signaling of steroid receptors in cancer2021 · 45 citations
2Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies2008 · 5,218 citations
3Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer2015 · 42 citations
4Membrane progesterone receptors in reproduction and cancer2016 · 117 citations
5Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study2007 · 163 citations

Bookmark

View Full Paper